Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BMO

Analysts Cheer Workday's Better Than Feared Q2 Amid Macro Concerns

Workday, Inc (NASDAQ:WDAY) clocked 21.9% revenue growth in Q2 to $1.54 billion, which beat average analyst estimates. The subscription revenues of $1.37 billion were up 22.8%. Workday reported EPS of $0.83, which beat average analyst estimates. Workday reported solid 2Q23 results highlighted with an uncertain macro backdrop pressuring sales much less than feared, Needham analyst…

Analysts Remain Cautious Over SAP Post Q2 Results

Analysts Remain Cautious Over SAP Post Q2 Results

Analysts remained divided with a cautious tone over SAP SE's (NYSE:SAP) prospects post Q2 results. Barclays analyst Raimo Lenschow saw SAP managing expectations into Q2, and the move lower in consensus halved the adj. EBIT miss. He found the FY guidance cut was unexpected, though, especially following reiterations in the quarter, and could not…

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Initiates Coverage On This Gene Editing Spearhead

BMO Capital initiated coverage of Intellia Therapeutics Inc (NASDAQ:NTLA) with a Market Perform rating and a $54 target price. The analyst says Intellia's gene-editing platform could potentially deliver transformative therapies. But challenges around the lack of clarity around an IND approval in the U.S., ongoing CRISPR/Cas9 IP litigations with Editas Medicine Inc (NASDAQ:EDIT), and high patient…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success

BMO Capital initiated coverage on Beam Therapeutics Inc (NASDAQ:BEAM) with a Market Perform rating and a price target of 41. BMO writes that it appreciates the high potential of Beam's next-generation editing approach, but clinical validation is yet to be established. Preclinical base editing data point to a favorable benefit/risk profile. Also Read: Pfizer, Beam…

BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock

BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ:GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors. BMO writes that Graphite's platform is expected to be safer than existing…

BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock

BMO Capital Markets initiated the coverage on Precision BioSciences Inc (NASDAQ:DTIL) with an Outperform rating and a price target of $7. The analyst said the thesis is based on: The company's proprietary gene-editing platform, whose mechanism is differentiated in a CRISPR-dominated space, offers several advantages. A diversified pipeline. Asymmetric risk/reward skewed to the upside.…

Read How Bank Of Montreal Fared In Q2

Bank of Montreal (TSX: BMO) (NYSE: BMO)

inkl

Read news from The Economist, FT, and more,
with one subscription

One Analyst Cuts Disney Price Target, Another Reiterates Buy Rating: Who's Right?

One Analyst Cuts Disney Price Target, Another Reiterates Buy Rating: Who's Right?

Walt Disney Co (NYSE: DIS) was featured as the call of the day Tuesday on CNBC's "Fast Money Halftime Report." Analysts Clash: BMO reiterated Disney with a Market Perform rating and cut the price target to $140 from $175.

Recap: Bank of Montreal Q1 Earnings

Recap: Bank of Montreal Q1 Earnings

Bank of Montreal (NYSE:BMO) reported its Q1 earnings results on Tuesday, March 1, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

1 2

People

Patrick Walravens

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play